Persistent increase of osteoprotegerin levels after cortisol normalization in patients with Cushing's syndrome

European Journal of Endocrinology

Volumn 162, Issue 1, 2010, Pages 85-90

  Camozzi, Valentina ^a   Sanguin, Francesca ^a   Albigier, Nora ^a   Scaroni, Carla ^a   Mantero, Franco ^a   Zaninotto, Martina ^a   Frigo, Annachiara ^a   Piccolo, Michele ^a   Luisetto, Giovanni ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTISONE ACETATE; HYDROCORTISONE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; CORTICOSTEROID THERAPY; CUSHING SYNDROME; DEXAMETHASONE SUPPRESSION TEST; FEMALE; FOLLOW UP; GONAD; HUMAN; OSSIFICATION; PRIORITY JOURNAL; BLOOD; COMPARATIVE STUDY; LONGITUDINAL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; BONE DENSITY; CUSHING SYNDROME; FEMALE; HUMANS; HYDROCORTISONE; LONGITUDINAL STUDIES; MIDDLE AGED; OSTEOPROTEGERIN; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 73949084842     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0800     Document Type: Article

References (37)

1. Vestergaard P, Lindholm J, Jørgensen JO, Hagen C, Hoeck HC, Laurberg P, Rejnmark L, Brixen K, Kristensen LØ, Feldt-Rasmussen U & Mosekilde L. Increased risk of osteoporotic fractures in patients with Cushing's syndrome. European Journal of Endocrinology 2002 146 51-56.
2. Pereira RM, Delany AM & Canalis E. Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone 2001 28 484-490.
3. Canalis E & Delany AM. Mechanisms of glucocorticoid action in bone. Annals of the New York Academy of Sciences 2002 966 73-81.
4. Lo Cascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, Tartarotti D & Della Rocca C. Bone loss in response to long-term glucocorticoid therapy. Bone and Mineral 1990 8 39-51.
5. Prummel MF, Wiersinga WM, Lips P, Sanders GT & Sauerwein HP. The course of biochemical parameters of bone turnover during treatment with corticosteroids. Journal of Clinical Endocrinology and Metabolism 1991 72 382-386.
6. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J & Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 93 165-176.
7. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T & Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998 139 1329-1337.
8. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S & Lacy DL. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. Journal of Cell Biology 1999 145 527-538.
9. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T & Higashio K. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochemical and Biophysical Research Communications 1998 253 395-400.
10. Weinstein RS, Jilka RL, Parfitt AM & Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. Journal of Clinical Investigation 1998 102 274-282.
11. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC & Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999 140 4382-4389.
12. Vidal NO, Brändström H, Jonsson KB & Ohlsson C. Osteoprotegerin mRNA is expressed in primary human osteoblasts-like cells: down regulation by glucocorticoids. Journal of Endocrinology 1998 159 191-195.
13. Sasaki N, Kusano E, Ando Y, Nemoto J, Iimura O, Ito C, Takeda S, Yano K, Tsuda E & Asano Y. Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. Bone 2002 30 853-858.
14. Ueland T, Bollerslev J, Godang K, Muller F, Froland SS & Aukrust P. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess-possible role in bone homeostasis. European Journal of Endocrinology 2001 145 685-690.
15. Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M & Dobnig H. Vascular calcification and osteoporosis: from clinical observation towards molecular understanding. Osteoporosis International 2007 18 251-259.
16. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ & Simonet WS. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes and Development 1998 12 1260-1268.
17. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA & Giachelli CM. Osteoprotegerin is an a b3-induced, NF-kB-dependent survival factor for endothelian cells. Journal of Biological Chemistry 2000 275 20959-20962.
18. Schoppet M, Sattler AM, Schaffer JR & Hofbauer L. Increased osteoprotegerin serum levels in men with coronary artery disease. Journal of Clinical Endocrinology and Metabolism 2003 88 1024-1028.
19. Arnaldi G, Mancini T, Polenta B & Boscaro M. Cardiovascular risk in Cushing's syndrome. Pituitary 2004 7 253-256.
20. Francucci CM, Pantanetti P, Garrapa GG, Massi F, Arnaldi G & Mantero F. Bone metabolism and mass in women with Cushing's syndrome and adrenal incidentaloma. Clinical Endocrinology 2002 57 587-593.
21. Mancini T, Kola B, Mantero F, Boscaro M & Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clinical Endocrinology 2004 61 768-777.
22. Pivonello R, Faggiano A, Lombardi G & Colao A. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinology and Metabolism Clinics of North America 2005 34 327-339.
23. Faggiano A, Pivonello R, Spiezia S, DeMartino MC & Colao AM. Cardiovascular risk factor and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. Journal of Clinical Endocrinology and Metabolism 2003 88 2527-2533.
24. Luisetto G, Zangari M, Camozzi V, Boscaro M, Sonino N & Fallo F. Recovery of bone mineral density after surgical cure, but not by Ketoconazole treatment, in Cushing's syndrome. Osteoporosis International 2001 12 956-960.
25. Di Somma C, Pivonello R, Loche S, Faggiano A, Klain M, Salvatore M, Lombardi G & Colao A. Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. Clinical Endocrinology 2003 58 302-308.
26. Füto L, Toke J, Patócs A, Szappanos A, Varga I, Gláz E, Tulassay Z, Rácz K & Tóth M. Skeletal differences in bone mineral area and content before and after cure of endogenous Cushing's syndrome. Osteoporosis International 2008 19 941-949.
27. Kristo C, Jemtland R, Ueland T, Godang K & Bollerslev J. Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study. European Journal of Endocrinology 2006 154 109-118.
28. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM & Montori VM. The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2008 93 1526-1540.
29. Day C. Metabolic syndrome, or what you will: definitions and epidemiology. Diabetes & Vascular Disease Research 2007 4 32-38.
30. von Tirpitz C, Epp S, Klaus J, Mason R, Hawa G, Brinskelle-Schmal N, Hofbauer LC, Adler G, Kratzer W & Reinshagen M. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. European Journal of Gastroenterology & Hepatology 2002 15 1165-1170.
31. Dovio A, Allasino B, Palmas E, Ventura M, Pia A, Saba L, Aroasio E, Terzolo M & Angeli A. Increased osteoprotegerin levels in Cushing's syndrome are associated with an adverse cardiovascular risk profile. Journal of Clinical Endocrinology and Metabolism 2007 92 1803-1808.
32. Kristo C, Ueland T, Godang K, Aukrust P & Bollerslev J. Biochemical markers for cardiovascular risk following treatment in endogenous Cushing's syndrome. Journal of Endocrinological Investigation 2008 31 400-405.
33. Hofbauer LC & Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. Journal of the American Medical Association 2004 292 490-495.
34. Browner WS, Lui LY & Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. Journal of Clinical Endocrinology and Metabolism 2001 86 631-637.
35. Shargorodsky M, Boaz M, Luckish A, Matas Z, Gavish D & Mashavi M. Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women. Atherosclerosis 2008 204 608-611.
36. Anand DV, Lahiri A, Lim E, Hopkins D & Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. Journal of the American College of Cardiology 2006 47 1850-1857.
37. Vik A, Mathiesen EB, Notø AT, Sveinbjørnsson B, Brox J & Hansen JB. Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis 2007 191 128-134.